You are here
- Hub home
- Support from MSD Animal Health
This page is intended for animal health professionals working in GB.
We have a variety of ways for you to receive additional information regarding the use of our products.
1. Your question may be answered by our Frequently Asked Questions below.
2. Email your question to our Technical Product Support Team, who will attempt to contact you by phone and/or email on the next working day. If possible, please provide a time we can contact you on the email and we will endeavour to contact you during this period.
3. Suspected adverse events and product quality concerns can be reported using our online form.
4. For non-technical questions e.g. account or Chameleon information, please use our contact form and we will send your query to the relvant team.
Common Suspected Adverse Event Questions
I've injected myself with an MSD Animal Health product or contaminated needle.
Needle-stick injuries associated with product use are adverse events, even if you don’t think a reaction to the product has occurred. They should be reported here – this vital information helps us give best practice advice in these situations.
The injury should be washed thoroughly and kept clean and dry to minimise the risks of infection. Medical advice should be sought, taking the product leaflet.
Potential concerns are:
- Injury from the needle itself
- Effects of the injected product
- Active ingredients - in most cases the antigens are non-pathogenic to humans but in all cases of self injection the datasheet should be consulted for specific advice.
- Excipients or adjuvants - please note that Nobivac®-branded vaccines DO NOT use mineral oil as an adjuvant so the chance of a serious adverse event is minimal. However, Rotavec® Corona, Footvax® and some Nobilis® vaccines DO contain mineral oil and self-injection can result in pain, swelling and serious injury without prompt medical attention (taking the packaging leaflet with you). For Scabivax®, Enzovax®, Toxovax® and Ringvac® please refer to the datasheet.
- Introduction of infection
- Skin contamination
- Vaccine components – with the exception of live bacterial vaccines such as Nobivac KC and Bb which contain Bordetella bronchiseptica, vaccines are sterile and should not cause infection.
I’ve given a vaccine dose in error - what should I do?
Incorrect administration should always be reported here, even if you don’t think a reaction has occurred. This includes giving a product to a species, or using a route or dose different from the datasheet and using out of date products. The information is used to keep our advice up to date.
For guidance on types of adverse signs for a specific vaccine, please refer to the datasheet or Summary of Product Characteristics.
Accidental injection of Nobivac KC or Nobivac Bb:
These vaccines contain live bacteria and are likely to cause an infection if given subcutaneously rather than the licensed intranasal route. Prompt treatment with a minimum 5-day course of an appropriate antibiotic is likely to prevent any serious consequences, but progress should be monitored. Please note that B.bronchiseptica is naturally resistant to cephalosporins.
I’ve overdosed a dog or cat with Bravecto® – should I be concerned?
An overdose should be reported here, even if you don’t think a reaction has occurred. These reports help us to give the best possible advice and monitor product performance.
The Bravecto product range has a wide dose margin of safety and the active constituent - fluralaner - is minimally metabolised with no known interactions with other classes of pharmaceuticals. Safety studies have been conducted in both dogs and cats.
The Bravecto Chewable Tablet product EPAR states;
Five TAS (Target Animal Safety) studies were conducted, of which two were reproductive safety studies. Fluralaner appears to be well tolerated when administered to Beagle puppies at up to 5X the maximum exposure dose on three occasions. At the recommended dose, Bravecto was in general well tolerated with common mild transient gastrointestinal events (diarrhoea, vomiting, inappetence and drooling). An appropriate warning has been included in the SPC (section 4.6). The product is safe for use in breeding, pregnant and lactating dogs.
For the Dog and Cat Bravecto Spot-on product at up to 5x maximum dose…
….fluralaner administered as a spot-on solution did not produce significant dose-related deviations in haematology, urinalysis and clinical chemistry (in comparison with control groups, with baseline levels or reference ranges derived from literature) and the incidental significant differences between treatment and control groups were considered not clinically relevant.1
Temporary hypersalivation and coughing may be seen following inappropriate oral ingestion of the spot-on in both dogs and cats, likely caused by the volatile excipients of the spot-on solution.
Further safety information is available from the datasheets.
A pet owner has spilled Bravecto Spot-on® on their skin - what should I advise?
Human administration should be reported here as an adverse event, even if no reaction seems to have occurred. The data is used to monitor product safety in the field, and enables us to give advice.
Bravecto Spot-on and Bravecto Plus are convenient long-acting products. The active ingredients are absorbed across the skin and are formulated to help the product adhere to the skin, minimise run off and ensure good absorption. To prevent accidental administration, the pipette has been designed to minimise spillage and the application instructions should be followed closely. Gloves should be worn.
If the product is accidentally applied, wash the area thoroughly with soap and water although in some cases not all the product will be removed. Please refer to the datasheet advice.
Report a Suspected Adverse Event
Use our online form to report a suspected adverse event including product quality concerns.
Ask a Technical Question
The information on this page is intended for animal health professionals working in Great Britain.
1. Target Animal Tolerance studies from the Bravecto Cat Spot-on EPAR